PRDM11 deficiency correlates with poorer survival in human DLBCL patients. (A) Human lymph node with follicular hyperplasia (I: hematoxylin and eosin (H&E); ×12.5) showing preferential labeling of PRDM11 in the germinal centers (II: PRDM11; ×12.5). The germinal center reaction is shown at a higher magnification (×200) in III; IV: H&E; V: PRDM11 staining of BCL6 illustrating that PRDM11 labels the GC (IV) similar to BCL6 (V), but also stains scattered small lymphocytes in the mantle zone (MZ). (B) Expression level of PRDM11 in sorted B-cell populations from 3 human tonsils measured by qRT-PCR. (C) Representative α-PRDM11 immunostainings from human DLBCLs with either low PRDM11 (left; scale bar = 20 µm) or high PRDM11 (right; scale bar = 20 µm). (D) Kaplan-Meier survival curves comparing the survival of DLBCL patients according to PRDM11 levels. Patients with low levels of PRDM11 have significantly poorer survival (P = .0237, log-rank test). (E) Number of PRDM11^lo or PRDM11^hi DLBCLs according to GCB and non-GCB subtypes.